NYSEMKT: PLXProtalix Biotherapeutics Inc Stock
$1.18+0.03 (+2.61%)
Updated Apr 22, 2024
PLX Price
$1.18
Fair Value Price
N/A
Market Cap
$86.20M
52 Week Low
$1.09
52 Week High
$3.55
P/E
9.83x
P/B
2.57x
P/S
1.84x
PEG
N/A
Dividend Yield
N/A
Revenue
$65.49M
Earnings
$8.31M
Gross Margin
64.9%
Operating Margin
15.97%
Profit Margin
12.7%
Debt to Equity
1.52
Operating Cash Flow
-$1M
Beta
0.64
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PLX Overview
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PLX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PLX is good value based on its earnings relative to its share price (9.83x), compared to the US market average (41x)
P/E vs Market Valuation
PLX is good value based on its earnings relative to its share price (9.83x), compared to the US Biotechnology industry average (16.21x)
P/E vs Industry Valuation
PLX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more PLX due diligence checks available for Premium users.
Be the first to know about important PLX news, forecast changes, insider trades & much more!
PLX News
Valuation
PLX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
9.83x
Industry
16.21x
Market
41x
PLX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PLX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PLX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.57x
Industry
5.82x
PLX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PLX's financial health
Profit margin
Revenue
$10.5M
Net Income
-$6.0M
Profit Margin
-57.6%
PLX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PLX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$84.4M
Liabilities
$50.9M
Debt to equity
1.52
PLX's short-term assets ($69.93M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PLX's short-term assets ($69.93M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PLX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PLX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$3.6M
Investing
-$342.0k
Financing
$0.0
PLX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PLX vs Biotech Stocks
Protalix Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.